Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00361335
Registration number
NCT00361335
Ethics application status
Date submitted
4/08/2006
Date registered
8/08/2006
Date last updated
29/07/2014
Titles & IDs
Public title
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Query!
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Query!
Secondary ID [1]
0
0
C0524T12
Query!
Secondary ID [2]
0
0
CR012781
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Golimumab
Treatment: Drugs - Methotrexate
Treatment: Drugs - Placebo
Experimental: Group I: 2mg/kg Golimumab + MTX - Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
Experimental: Group II: 2mg/kg Golimumab only - IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
Experimental: Group III: 4mg/kg Golimumab + MTX - IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
Experimental: Group IV: 4mg/kg Golimumab only - IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
Placebo comparator: Group V: IV Placebo + MTX - IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
Treatment: Drugs: Golimumab
2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
Treatment: Drugs: Methotrexate
Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
Treatment: Drugs: Placebo
Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With an American College of Rheumatology (ACR) 50 Response at Week 14
Query!
Assessment method [1]
0
0
An ACR 50 response is defined as a greater than or equal to 50 percentage improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain (VAS) (0-10 cm) b. Patient's Global Assessment of Disease activity (VAS) (0-10 cm) c. Physician's Global Assessment of Disease Activity (VAS) (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein (CRP).
Query!
Timepoint [1]
0
0
Week 0 to Week 14
Query!
Secondary outcome [1]
0
0
Number of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24
Query!
Assessment method [1]
0
0
ACR 50 response is an improvement of greater than or equal to 50 percentage from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain, patient's global assessemnt of disease activity, Physician's global assessment of disease activity (based on a scale of 0=no disease to 10=severe disease), HAQ (20 questions on life activities) and CRP blood test to measure inflammation).
Query!
Timepoint [1]
0
0
Week 0 to Week 24
Query!
Secondary outcome [2]
0
0
Number of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14
Query!
Assessment method [2]
0
0
ACR 20 response is an improvement of greater than or equal to 20 percentage from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain, patient's global assessemnt of disease activity, Physician's global assessment of disease activity \[based on a scale of 0=no disease to 10=severe disease), HAQ (20 questions on life activities\] and CRP blood test to measure inflammation).
Query!
Timepoint [2]
0
0
Week 0 to Week 14
Query!
Secondary outcome [3]
0
0
Number of Participants With a Disease Activity Index Score 28 (Using C-reactive Protein)Moderate or Good Response at Week 14
Query!
Assessment method [3]
0
0
DAS28 using CRP is a measure of tender and swollen joints (28 joints each) and the patient's assessment of disease activity. Values range from 0 (best) to 10 (worst). A score of higher than 5.1 indicates high disease activity, and a score below 3.2 indicates low disease activity. A "Good" response is defined as a patient with a DAS28 score of \<= 3.2 at Week 14 with improvement from Baseline in DAS28 score of \> 1.2. A "Moderate" response is defined as a patient with DAS28 score of \>3.2-5.1 at Week 14 with improvement from baseline in DAS28 score of \>1.2 or a DAS28 score of \<= 5.1 and improvement from baseline in DAS28 score of \>0.6 to 1.2
Query!
Timepoint [3]
0
0
Week 0 to Week 14
Query!
Secondary outcome [4]
0
0
Physical Component Summary (PCS) Score of the Short Form-36 (SF-36) at Week 14
Query!
Assessment method [4]
0
0
The SF-36 consists of 8 multi-item scales: limitations in physical functioning due to health problems, usual role activities due to physical health problems, bodily pain, usual role activities due to personal or emotional problems, social functioning due to physical or mental health problems, general mental health (psychological distress and well-being), vitality and general health perception. The values are 100=best to 0=worst.
Query!
Timepoint [4]
0
0
Weeks 0 to Week 14
Query!
Eligibility
Key inclusion criteria
- Must have a diagnosis of active rheumatoid arthritis (RA) (according to the revised 1987 criteria of the ARA (American Rheumatism Association) with at least 4 swollen and 4 tender joints for at least 3 months prior to screening - Have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg per week for at least 3 months prior to screening - Have been on a stable MTX dose of greater than or equal to 15 mg per week and less than or eual to 25 mg per week for at least 4 weeks prior to screening - If using non steroidal anti-inflammatory agents (such as naproxen) or other pain relievers for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Participants having known hypersensitivity (severe allergy) to human immunoglobulin proteins or other components of golimumab - Having known clinically serious adverse reaction to a biologic anti-TNF agent - Have had history of latent or active granulomatous infection, including tuberculosis, histoplasmosis, or coccidioidomycosis, prior to screening
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
643
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Fitzroy
Query!
Recruitment hospital [2]
0
0
- Heidelberg
Query!
Recruitment hospital [3]
0
0
- Maroochydore
Query!
Recruitment hospital [4]
0
0
- Melbourne
Query!
Recruitment hospital [5]
0
0
- Perth
Query!
Recruitment hospital [6]
0
0
- Woodville
Query!
Recruitment postcode(s) [1]
0
0
- Fitzroy
Query!
Recruitment postcode(s) [2]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [3]
0
0
- Maroochydore
Query!
Recruitment postcode(s) [4]
0
0
- Melbourne
Query!
Recruitment postcode(s) [5]
0
0
- Perth
Query!
Recruitment postcode(s) [6]
0
0
- Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Nebraska
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New Jersey
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Oklahoma
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Pennsylvania
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Buenos Aires
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Cordoba
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Rosario
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
San Juan
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
San Miguel De Tucuman
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Santa Fe
Query!
Country [18]
0
0
Colombia
Query!
State/province [18]
0
0
Barranquilla
Query!
Country [19]
0
0
Colombia
Query!
State/province [19]
0
0
Bogota
Query!
Country [20]
0
0
Colombia
Query!
State/province [20]
0
0
Bucaramanga
Query!
Country [21]
0
0
Colombia
Query!
State/province [21]
0
0
Floridablanca
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Erlangen
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Hamburg
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Magdeburg
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
München
Query!
Country [26]
0
0
Hungary
Query!
State/province [26]
0
0
Budapest
Query!
Country [27]
0
0
Hungary
Query!
State/province [27]
0
0
Szolnok
Query!
Country [28]
0
0
Latvia
Query!
State/province [28]
0
0
Daugavpils
Query!
Country [29]
0
0
Latvia
Query!
State/province [29]
0
0
Riga
Query!
Country [30]
0
0
Lithuania
Query!
State/province [30]
0
0
Kaunas
Query!
Country [31]
0
0
Lithuania
Query!
State/province [31]
0
0
Klaipeda
Query!
Country [32]
0
0
Lithuania
Query!
State/province [32]
0
0
Siauliai
Query!
Country [33]
0
0
Lithuania
Query!
State/province [33]
0
0
Vilnius
Query!
Country [34]
0
0
Malaysia
Query!
State/province [34]
0
0
Ipoh
Query!
Country [35]
0
0
Malaysia
Query!
State/province [35]
0
0
Kuching
Query!
Country [36]
0
0
Malaysia
Query!
State/province [36]
0
0
Precinct 7
Query!
Country [37]
0
0
Malaysia
Query!
State/province [37]
0
0
Selangor Darul Ehasan
Query!
Country [38]
0
0
Malta
Query!
State/province [38]
0
0
Msd06 Gwardiamangia
Query!
Country [39]
0
0
Mexico
Query!
State/province [39]
0
0
Col. Del Valle
Query!
Country [40]
0
0
Mexico
Query!
State/province [40]
0
0
Guadalajara Jalisco
Query!
Country [41]
0
0
Mexico
Query!
State/province [41]
0
0
Guadalajara N/A
Query!
Country [42]
0
0
Mexico
Query!
State/province [42]
0
0
Monterrey
Query!
Country [43]
0
0
New Zealand
Query!
State/province [43]
0
0
Christchurch
Query!
Country [44]
0
0
New Zealand
Query!
State/province [44]
0
0
Dunedin
Query!
Country [45]
0
0
New Zealand
Query!
State/province [45]
0
0
Rotorua
Query!
Country [46]
0
0
New Zealand
Query!
State/province [46]
0
0
Takapuna Auckland
Query!
Country [47]
0
0
New Zealand
Query!
State/province [47]
0
0
Timaru
Query!
Country [48]
0
0
Peru
Query!
State/province [48]
0
0
Lima
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Bialystok
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Elblag
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Krakow
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Warszawa
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Wloszczowa
Query!
Country [54]
0
0
Ukraine
Query!
State/province [54]
0
0
Kiev
Query!
Country [55]
0
0
Ukraine
Query!
State/province [55]
0
0
Kyiv
Query!
Country [56]
0
0
Ukraine
Query!
State/province [56]
0
0
Symferpol
Query!
Country [57]
0
0
Ukraine
Query!
State/province [57]
0
0
Zhaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Centocor, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Schering-Plough
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid arthritis (RA) despite concurrent MTX treatment. In addition, the safety of subcutaneous (SC) golimumab injections following transition from IV golimumab infusions will also be evaluated.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00361335
Query!
Trial related presentations / publications
George MD, Ostergaard M, Conaghan PG, Emery P, Baker DG, Baker JF. Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. Ann Rheum Dis. 2017 Oct;76(10):1743-1746. doi: 10.1136/annrheumdis-2017-211569. Epub 2017 Jun 12. Baker JF, Conaghan PG, Smolen JS, Aletaha D, Shults J, Emery P, Baker DG, Ostergaard M. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol. 2014 Apr;66(4):794-802. doi: 10.1002/art.38304. Baker JF, Baker DG, Toedter G, Shults J, Von Feldt JM, Leonard MB. Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis. Clin Exp Rheumatol. 2012 Sep-Oct;30(5):658-64. Epub 2012 Oct 17. Taylor PC, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Mack M, Kremer J. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. J Rheumatol. 2011 Dec;38(12):2572-80. doi: 10.3899/jrheum.110570. Epub 2011 Nov 15. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010 Apr;62(4):917-28. doi: 10.1002/art.27348. Erratum In: Arthritis Rheum. 2010 Oct;62(10):3130.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Centocor, Inc. Clinical Trial
Query!
Address
0
0
Centocor, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00361335
Download to PDF